Phase 2
N=20
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
Peanut Allergy
Bottom Line
View on ClinicalTrials.gov: NCT05138757 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: The Proportion of Subjects Mildly Symptomatic or Less at the 12 Month DBPCFC — 4; 4 Participants — p=1.00
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Prebiotic (Drug); Placebo (Drug)
- Age
- Pediatric · 4+ yrs
- Sex
- All
- Sponsor
- University of Chicago
- Primary completion
- Mar 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Proportion of Subjects Mildly Symptomatic or Less at the 12 Month DBPCFC |
4; 4 | 1.00 |
| SECONDARY The Proportion of Subjects Who Experience Dose Related GI Side Effects During Oral Immunotherapy |
4; 7 | 0.65 |
| SECONDARY The Proportion of Subjects Who Experience Hypersensitivity Reactions (Other Than GI) During Oral Immunotherapy |
3; 5 | 0.66 |
Summary
The purpose of this research is to gather information on the safety and efficacy of using a prebiotic as an adjunctive therapy to peanut oral immunotherapy. The prebiotic is not an FDA approved drug or medication rather a fiber found at local grocery stores.
Eligibility Criteria
Inclusion Criteria
- Age 4 to 17 (inclusive)
- A convincing clinical history of peanut allergy
- Immune markers consistent with peanut allergy
- Serum IgE to peanut of >0.35 kUA/L and a skin prick test to peanut >8mm greater than the negative saline control -or-
- Serum IgE to peanut of >5 kUA/L and a mean peanut wheal diameter on skin prick test 3 to 8mm greater than the negative saline control -or-
- Serum IgE to peanut of >14 kUA/L and mean peanut wheal diameter on skin prick test 3mm greater than the negative saline control
- Experience dose-limiting symptoms at or before 100mg challenge dose of peanut protein on screening double blind placebo-controlled food challenge (DBPCFC)
- Written informed consent from parent/guardian
- Written assent from subjects above the age of 7
Exclusion Criteria
- • History of a chronic disease (other than asthma, allergic rhinitis, and atopic dermatitis) that is at significant risk of becoming unstable or requiring a change in chronic therapeutic regimen
- History of mast cell disease
- History of recurrent idiopathic or virally induced urticaria, angioedema or anaphylaxis
- Any history or presence of autoimmune, cardiovascular disease, chronic lung disease (other than asthma), malignancy, psychiatric illness, or gastrointestinal inflammatory conditions, including celiac disease, inflammatory bowel disease, eosinophilic esophagitis or other eosinophilic gastrointestinal disease
- Current participation in any other interventional study
- Subject who has undergone any type of oral immunotherapy
- Severe asthma or uncontrolled mild to moderate asthma
- Uncontrolled atopic dermatitis
- Current use of oral steroid medications
- Use of >1 bursts of oral steroid medications in the past year
- Inability to eat by mouth the fiber supplementation or placebo control and peanut flour for any reason
- Use of any therapeutic antibody (biologic medication) or any immunomodulatory medication in the past 12 month (other than a short course of oral steroids)
- Current use of any type of immunotherapy
- Pregnancy or lactation
- Allergy to potato or corn oat or cow's milk
- Unwillingness to carry an epinephrine auto-injector
- Unwillingness to comply with activity restrictions during OIT or any other study procedure
Data sourced from ClinicalTrials.gov (NCT05138757). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.